The burden of drug overdose deaths among correctional populations: implications for interventions Authors: Benedikt Fischer, Elnaz Moghimi, John Weekes Published: 2024 KEY POINTS Correctional populations are characterized by disproportionately elevated levels of chronic diseases, including substance use and mental health disorders. Correctional populations are characterized by disproportionately elevated levels of chronic diseases, including substance use and mental health disorders. In contexts of the present drug overdose death crisis driven by synthetic toxic opioids, increasing numbers of drug overdose deaths have been observed among incarcerated people in Canada. In contexts of the present drug overdose death crisis driven by synthetic toxic opioids, increasing numbers of drug overdose deaths have been observed among incarcerated people in Canada. Rates of drug overdose deaths among corrections-exposed populations are estimated to be higher than those observed in general populations. Rates of drug overdose deaths among corrections-exposed populations are estimated to be higher than those observed in general populations. Intervention uptake, additional implementation, and expansion of measures to prevent harms related to substance use in Canada’s prisons are needed. Intervention uptake, additional implementation, and expansion of measures to prevent harms related to substance use in Canada’s prisons are needed. In this issue of CMAJ, Houdroge and colleagues present a cost–benefit analysis of expanding needle exchange programs across federal prisons in Canada and conclude that doing so would lead to substantial health care–related savings, particularly in the area of preventing transmissions of infections.1 Incarceration-exposed individuals in Canada are disproportionately affected by a wide range of chronic diseases, including mental health and substance use disorders. Prison populations are not exempt from the devastating crisis of drug-related overdose deaths that has been unfolding across North America over the last decade. More comprehensive interventions to make substance use in correctional institutions safer, and specifically reduce related risks of acute death, are needed. We discuss substance use–related harm in correctional environments, efforts and measures developed to mitigate it, and how interventions can be expanded to improve the substance use–related health of incarcerated people in Canada. The prevalence of substance use disorders among incarcerated populations has been estimated at 50% or more; in Canada, as many as 1 in 3 federal prison inmates reported in recent surveys that they had used drugs in the last 6 months while incarcerated.2,3 Prisoners experience highly elevated rates of all-cause mortality, both during but especially immediately after release from incarceration. A recent systematic review identified substance-related poisonings as the leading specific cause of death (crude mortality ratio 657, 95% confidence interval 332–1076) among incarceration-exposed individuals in the initial week after release, indicating a profoundly adverse risk–harm nexus between substance use, correctional environments, and mortality, which is further mediated by additional risk factors.4 With the ongoing drug death crisis, drug-related overdose fatalities have become the leading cause of non-natural deaths in the general population, largely driven by the dominant illicit and toxic supply of synthetic opioids, mainly fentanyl or fentanyl analogues, while commonly combined or further contaminated with other harmful substances. One might ask how this crisis has specifically affected incarceration-exposed populations, but the question is not easily answered. Among the documented caseload of 19 people who died of drug-related overdose in the federal correctional system in a recent 3-year period (2017/18–2019/20), opioids were involved in all but 2 cases with investigations complete; all but 1 of the opioid-related deaths involved fentanyl.5 Drawing on data from several sources, one can estimate that over recent years, incarcerated people have experienced an even higher rate of drug-related overdose death than measured for the general population in Canada.5,6 In Ontario, where fentanyl or analogue substances have been the primary driver of drug-related overdose deaths over the last decade, 8460 acute toxicity deaths related to opioids were reported between 2015 and 2020; 2207 (26.1%) of these opioid-related overdose deaths involved incarceration-exposed people, resulting in a crude mortality rate per 10 000 person-years for incarceration-exposed individuals that was 45 times higher than for nonexposed individuals.7 Although various non-opioid (e.g., stimulant or prescription medications) substances also contribute to overdoses, toxic fentanyl substances have been burden in Canadian incarceration-exposed populations.5–7 Although the drug-related overdose death crisis is a highly complex problem to solve in general community contexts, challenges are even greater in prison settings for many reasons, not least because correctional institutions in Canada mostly remain, officially, framed as “drug-free” environments.8,9 However, important efforts and measures to reduce substance use–related harm in correctional environments have been established that can be expanded and built upon. For example, while somewhat inconsistent, evidence suggests that medication-supported therapy (e.g., methadone, buprenorphine) for opioid use disorder (MOUD) is effective in reducing the hazards of (fatal and nonfatal) overdose among corrections-exposed people, both during incarceration and after release.10 Engagement with MOUD in Canadian correctional populations has substantially increased in recent years and should be systematically expanded to all inmates with opioid use disorder, including novel MOUD formulations (e.g., extended-release), per community-based best practice standards.11,12 Special attention needs to be paid to improving and extending care transitions for prisoners upon release, since MOUD is commonly interrupted in contexts of wider reintegration challenges after community release. This, combined with elevated vulnerabilities (e.g., reduced biological tolerance, increased or drug access), can trigger relapse and so increase the risk of overdose.13,14 Access to (including training for) take-home naloxone provisions for opioid-overdose reversal comprises simple and largely standard elements of correctional release programming; not-withstanding some systemic implementation challenges in addition to naloxone’s efficacy limitations for fentanyl or analogue substances, this has been shown to reduce drug-related overdose deaths after release.15 Other interventions that have proven effective in preventing overdoses are available in community but are currently limited or unavailable within prison settings in Canada; these should be considered for adaptation toward implementation or extension in prisons. For example, supervised consumption or overdose prevention sites are now widely available, effective community-based interventions to reduce acute risk behaviours for overdose. An initial experimental overdose prevention facility has been implemented in the federal correctional system (Drumheller Institution, Alberta), for which initial evaluative evidence indicated reduced overdose-relevant risk behaviours among program participants and increasing inmate and staff support. 16,17 Although a couple of additional overdose prevention sites have reportedly been established in other federal correctional institutions, comprehensively expanding — while rigorously evaluating — overdose prevention sites in prisons would likely help reduce systemic overdose risks among incarcerated people. Then, “safer drug supply” programming — which provides pharmaceutical-grade substances (e.g., opioids) via different delivery modes to prevent toxic drug exposure among people involved in high-risk drug use — has been implemented in general community settings across Canada. It has been shown to reduce overdose-related risk, drug-related overdose death outcomes, and adverse health status among program participants.18,19 Safer drug supply programs could be experimentally adapted for use in correctional settings for those with known active high-risk drug use involvement, either during incarceration or as part of release-transition linkages, or both. Prison-based programs aimed at mitigating the health harms of substance use by correctional inmate populations should be carefully evaluated as part of their implementation, as has been done by Houdroge and colleagues in the related research with specific respect to needle exchange programs. Without systematic expansion of and increased access to such programs, prisoners in Canada will remain at unnecessarily high risk of ill health and death from the adverse consequences of substance use. See related research at www.cmaj.ca/lookup/doi/10.1503/cmaj.240648 Footnotes Competing interests: Benedikt Fischer has received select research grants and contracts regarding issues of substance use epidemiology, interventions, and policy from public funding or government agency (i.e., public-only) sources. Dr. Fischer is also the lead investigator of a Correctional Service Canada–funded memorandum of understanding for research on substance use and mental health in federal corrections (funding paid to academic institution). No other competing interests were declared. This article was solicited and has not been peer reviewed. Contributors: Benedikt Fischer contributed to the conception and design of the work and drafted the manuscript. Elnaz Moghimi and John Weekes revised it critically for important intellectual content. All of the authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work. References